Cyclic AMP comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
A PSMA scan is a nuclear medicine imaging technique used in the diagnosis and staging of prostate cancer. It is carried out by injection of a radiopharmaceutical with a positron or gamma emitting radionuclide and a prostate-specific membrane antigen (PSMA) targeting ligand. After injection, imaging of positron emitters such as gallium-68 (68Ga), copper-64 (64Cu), and fluorine-18 (18F) is carried out with a positron emission tomography (PET) scanner. For gamma emitters such as technetium-99m (99mTc) and indium-111 (111In) single-photon emission computed tomography (SPECT) imaging is performed with a gamma camera. As well as the diagnosis and staging of prostate cancer, PSMA imaging can also be used to assess suitability for and plan treatment with external beam radiotherapy and PSMA-targeted radionuclide therapy.
== Greek fortifications == The oldest discoveries were made in the northwestern part and involved a portion of the north–south road which dates back to the 6th century BC. A first rampart made up of a white limestone base from Saint-Victor surmounted by an elevation in raw clay bricks dating from the end of the 5th century BC was also discovered. These fortifications must have been contemporaneous with the large public well, which has now disappeared, located to the north of the area. This archaic rampart was then rebuilt, probably in the second half of the 4th century BC. This new rampart seems to have included, like the previous one, a stone plinth surmounted by an elevation made of large blocks of tuff which replaced the raw bricks. A gate opening onto the route d'Italie in an east–west direction is flanked by two towers or bastions. This wall is clearly visible in the northwest corner of the current garden, preceded by a ditch. In the second half of the 2nd century BC, the rampart was rebuilt on a large scale, this time in blocks of pink limestone from Cape Couronne, transported by boat. It is this rampart that defended the city during the siege of Julius Caesar in 49 BC. It would remain in use until the beginning of the Middle Ages. The wall was built according to a usual technique of Greek military architecture with two facings built with standardized blocks, the interior being filled with residues from the cutting of blocks or stones from the old rampart. From north to south are:
== Pharmacokinetics == Butyrfentanyl binds to the opioid receptor. During the studies of in vitro inhibition of specific [3H] fentanyl binding to the opioid receptor, the order of analogues was: (±)-cis-3-methylfentanyl > fentanyl = alpha-methylfentanyl > butyrylfentanyl > benzylfentanyl. The studies in inhibition studies on binding affinity achieved the same order of analogues. It means that butyrfentantyl is a less potent opioid-agonist than fentanyl. On the other side, during in vitro studies of cross-reactivity with the fentanyl antibody between fentanyl and the fentanyl analogs examined, revealed order: fentanyl = butyrylfentanyl > (±)-cis-3-methylfentanyl > benzylfentanyl > alpha-methylfentanyl. High cross-reactivity may be the effect of the shape of the molecule — the shape of butyrfentanyl is closest to the original fentanyl molecule, which makes it easy to bind by fentanyl antibodies. The opioid receptor affinity of fentanyl and its analogs was determined from their inhibitory potency in a binding assay with [3H] fentanyl as the radioligand. The Ki value for butyrfentanyl was 32 ± 4.1 nM. Comparing to fentanyl's Ki (1.06 ± 0.15 nM), butyrfentanyl's ability to displace [3H] fentanyl is low and it requires high concentrations of the drug. Studies on urinary excretion revealed that almost all of the injected butyrfentanyl was excreted or metabolized within the first 3 hours after injection, and only very low concentrations were still detectable after 3 hours. Urinary concentrations of butyrylfentanyl from animals injected with 15 μg/kg and 45 μg/kg i.v.
The α-globin chains are encoded by two closely linked genes HBA1 and HBA2 on chromosome 16; in a person with two copies on each chromosome, a total of four loci encode the α chain. Two alleles are maternal and two alleles are paternal in origin. Alpha-thalassemias result in decreased alpha-globin production, resulting in an excess of β chains in adults and excess γ chains in fetus and newborns.
endogenous Originating or arising inside of an organism or cell; produced by the organism or cell itself, rather than sourced from the external environment; of or pertaining to native or internal factors or processes, to be distinguished from foreign or exogenous factors or processes.
Sources: en.wikipedia.org
The practical role of protein structure prediction is now more important than ever. Massive amounts of protein sequence data are produced by modern large-scale DNA sequencing efforts such as the Human Genome Project. Despite community-wide efforts in structural genomics, the output of experimentally determined protein structures—typically by time-consuming and relatively expensive X-ray crystallography or NMR spectroscopy—is lagging far behind the output of protein sequences. The protein structure prediction remains an extremely difficult and unresolved undertaking. The two main problems are the calculation of protein free energy and finding the global minimum of this energy. A protein structure prediction method must explore the space of possible protein structures which is astronomically large. These problems can be partially bypassed in "comparative" or homology modeling and fold recognition methods, in which the search space is pruned by the assumption that the protein in question adopts a structure that is close to the experimentally determined structure of another homologous protein. In contrast, the de novo protein structure prediction methods must explicitly resolve these problems. The progress and challenges in protein structure prediction have been reviewed by Zhang.
=== Familia Presto series 1 (FA3; 1970) === From April 1970, the Presto nameplate was added into the entire Familia range, "Presto" means "quick" in Italian. Brand new overhead camshaft 1.3-litre TC engine also appeared, derived from the smaller 1.0-litre OHC engine already seen in the first generation Familia coupé. At the same time, the range received a light facelift including a chrome strip around the front grille. Unlike the pickup, the vans also used the "Familia Presto" name. Chassis codes are SPCV for the 1.0-litre and STBV for the 1.3-litre model, with power outputs as for the saloon/coupé. Standard and Deluxe versions were available, with the Deluxe also offering five-door bodywork. The Familia was exported as the "Mazda 1300", and replaced the previous generation 1200 model in most markets. In Finland, the Familia Presto was marketed as the "Mazda Marella." The saloon and coupé were updated in 1972 in Japan and in the autumn of 1973 for export market, but the pickup and wagon/van versions continued with little change. The vans and pickups actually soldiered on until 1978, by which time a wagon version of the succeeding FA4 Familia (323/GLC) had been introduced. The later pickup versions were also available in a long-wheelbase version, and still featured an 85 PS (63 kW) (SAE gross) version of the 1.3-litre TC engine, unaffected by the tighter Japanese emissions standards for passenger cars. The "1200" was offered in the United States in 1971 and again for the 1973 model year.
== Myths == A common myth among radar and microwave communication workers is that the exposure of the genital area to microwaves renders a man sterile for about a day. The power density necessary for this effect is however sufficient to also cause permanent damage.
=== Pharmacokinetics === While riluzole is typically taken twice-daily and on an empty stomach, troriluzole may offer a potential once-daily dosing with or without food along with greater bioavailability.
By the 1970s, chemotaxonomic surveys were uncovering dozens of chemically defined species, underscoring the extent of cryptic diversity. One review reported 240 distinct chemical variants across 99 examined morphospecies. Subsequent DNA studies confirmed that many variants correspond to distinct lineages. Two chemical forms of the long-recognized Parmeliopsis ambigua illustrate this pattern. One form contains usnic acid, the other atranorin. These proved to be separate species when molecular data showed they are not sister taxa. Chemical characters remain central to routine identification and increasingly inform conservation assessments. A 2024 herbarium study of the rare Brodoa oroarctica uncovered misidentified records; only classic spot tests (K, C, Pd) and TLC clarified the species' true range, demonstrating the ongoing value of traditional chemical tools beside modern molecular methods.
Sources: en.wikipedia.org
== References == Carlsson, J.; Forssell Aronsson, E; Hietala, SO; Stigbrand, T; Tennvall, J; et al. (2003). "Tumour therapy with radionuclides: assessment of progress and problems". Radiotherapy and Oncology. 66 (2): 107–117. doi:10.1016/S0167-8140(02)00374-2. PMID 12648782. "Radioisotopes in Industry". World Nuclear Association. Archived from the original on 27 February 2013. Retrieved 2 May 2008. Martin, James (2006). Physics for Radiation Protection: A Handbook. John Wiley & Sons. p. 130. ISBN 978-3527406111.
== Critical reception == Thomas's work and stature as a poet have been much debated by critics and biographers since his death. Critical studies have been clouded by Thomas's personality and mythology, especially his drunken persona and death in New York. When Seamus Heaney gave an Oxford lecture on the poet he opened by addressing the assembly, "Dylan Thomas is now as much a case history as a chapter in the history of poetry", querying how "Thomas the Poet" is one of his forgotten attributes. The Poetry Archive notes that "Dylan Thomas's detractors accuse him of being drunk on language as well as whiskey, but whilst there's no doubt that the sound of language is central to his style, he was also a disciplined writer who re-drafted obsessively". David Holbrook, who has written three books about Thomas, stated in his 1962 publication Llareggub Revisited, "the strangest feature of Dylan Thomas's notoriety—not that he is bogus, but that attitudes to poetry attached themselves to him which not only threaten the prestige, effectiveness and accessibility to English poetry but also destroyed his true voice and, at last, him." Holbrook's negative evaluation of Thomas's work, based on an ad hominem psychoanalytic reading, is rejected by Rhian Barfoot as reductive and outdated viewed in the context of more recent psychoanalytic theory as found in the work of Lacan and Kristeva, where the emphasis on the semiotic and the materiality of language is seen as corresponding to Thomas's poetic style and thus supportive of a positive critical evaluation of his work.
The Augustus of Prima Porta (Italian: Augusto di Prima Porta) is a full-length portrait statue of Augustus, the first Roman emperor. The statue was discovered on April 20, 1863, during archaeological excavations directed by Giuseppe Gagliardi at the Villa of Livia owned by Augustus's third and final wife, Livia Drusilla in Prima Porta. Livia had retired to the villa after Augustus's death in AD 14. Its discovery was first publicized by the German archaeologist Wilhelm Henzen the same year. The marble statue was carved in the 1st century AD by skilled sculptors who may have been Greek, although this is not certain. The piece is generally believed to be a copy of a lost bronze original displayed in Rome. It blends Greek and Roman elements to craft an idealized official image of Augustus, showcasing his grasp of visual influence. While the head portrays a realistic youthful Augustus, the body diverges from reality; despite its clothed form, the body's stance reflects the heroic stance found in Greek statues. The detailed armor, depicting a Parthian returning standards to a Roman, symbolizes peace along the eastern frontier of the Roman Empire. The statue stands 2.08 metres (6 ft 10 in) tall and weighs 1,000 kilograms (2,200 lb). The Augustus of Prima Porta is now displayed in the Braccio Nuovo (New Arm) of the Vatican Museums. Since its discovery, it has become the best known of Augustus's portraits and one of the most famous sculptures of the ancient world.
Sandra Jill James is a retired American biochemist and autism researcher who studied metabolic autism biomarkers. She worked at Arkansas Children's Hospital Research Institute, where she was the director of the Metabolic Genomics Laboratory, as well as the University of Arkansas for Medical Sciences' department of pediatrics, where she began working in 2002. She was also a member of the Autism Speaks Treatment Advisory Board. James' research focused on the role of epigenetics in autism, as well as the effectiveness of supplements as a treatment for autism and the potential existence of abnormal metabolism in autistic children. This research was previously funded by a 5-year grant from the National Institutes of Health entitled "Metabolic biomarkers of autism: predictive potential and genetic susceptibility", as well as by a grant from Autism Speaks. James has falsely speculated that the thiomersal used as a preservative in some vaccines is potentially harmful to the human brain and that prophylactic supplements may protect against such harm preceding vaccination.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.